MitoImmune Therapeutics Inc. products

Hepatic fibrosis is pre-stage of hepatocirrhosis; High unmet demand for interruption of liver fibrosis.

MIT-001 is expected to meet the medical need for oral mucositis for which there is no cure. It aims to be a first-in-class drug that can be used by both patients with head and neck cancer or hematological cancer with a high incidence and severity of oral mucositis as a side effect of chemoradiation therapy.

MIT-001 is an innovative clinical candidate that blocks the root cause of graft-versus-host disease, which often occurs during allogenic hematopoietic stem cell transplantation (HSCT), through a mechanism of action that is differentiated from any current treatment.

Cell death was mainly divided into apoptosis and necrosis, but recent studies have revealed that there are new mechanisms of cell death with biological processes and pathophysiological characteristics besides apoptosis and necrosis. According to the recent recommendation of the Nomenclature Committee of Cell Death, , cell death is divided into apoptosis, autophagy, ferroptosis, pyroptosis, necroptosis, and necrosis, depending on the presence of a molecular mechanism and the release of inflammatory factors. Regulated nectotic cell death including ferroptosis, pyroptosis, and necroptosis causes inflammation by releasing potent pro-inflammatory factors.

MIT platform is a MitoImmune’s proprietary technology that is centered 7-amino indole core structure. MIT compounds based the platform have a unique capability to permeate into negatively charge mitochondrial matrix. The MIT platform inhibits ferroptosis and blocks the DAMPs release and cytokine storm.